Sale disclosed
Kimberly Manhard
Director
Common Stock
- Reported value
- $55.89K
- Reported price
- $111.775 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Inhibrx Biosciences, Inc.
Last 30 daysInsiders bought $5.5M · 3 buyers, led by Mark Lappe (CEO) with $3.64M. Sales: $279.01K by 1 insider.
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockSale | 500$111.78 / share | $55.89K | Sep 11Filed Sep 15 · 4d later | SEC filing |
| Director | Common StockSale | 500$110.26 / share | $55.13K | Sep 14Filed Sep 15 · 1d later | SEC filing |
| Director | Common StockSale | 500$105.05 / share | $52.53K | Sep 15Filed Sep 15 · 0d later | SEC filing |
| Director | Common StockSale | 500$115.14 / share | $57.57K | Sep 8Filed Sep 10 · 2d later | SEC filing |
| Director | Common StockSale | 500$115.80 / share | $57.9K | Sep 9Filed Sep 10 · 1d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
$5,098,421 of common-equity purchase value after transaction-age decay across 180 days.
3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
3 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
A reporting-owner group bought on at least two distinct dates within the cluster window.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.